Yerushalmi Rinat, Kennecke Hagen, Woods Ryan, Olivotto Ivo A, Speers Caroline, Gelmon Karen A
Division of Medical Oncology, British Columbia Cancer Agency, 600 w 10th Avenue, Vancouver, BC, Canada V5Z 4E6.
Breast Cancer Res Treat. 2009 Sep;117(2):365-70. doi: 10.1007/s10549-008-0265-1. Epub 2008 Dec 11.
Purpose we evaluated whether patients with multifocal/multicentric (M/M) breast cancer have different outcomes compared to unifocal (U) disease in terms of survival and the development of contralateral breast cancer (CBC) disease. Methods women diagnosed with stage I-III breast cancer were classified as having U or M/M disease. Prognostic factors were prospectively collected and obtained from the breast cancer outcome unit database. Univariate and multivariable analyses for the incidence of CBC were performed as well as Kaplan-Meier plots. Results 25,320 women met inclusion criteria. The 5-year cumulative incidence of CBC in the U versus M/M group was 2.3% (95% CI 2.1, 2.5) versus 2.4% (95% CI 1.6, 3.4) (P = 0.349). Breast cancer specific survival (BCSS) rate revealed a slightly worse outcome with M/M disease, RR = 1.174 (95% CI 1,004, 1.372). Conclusions M/M breast cancer did not increase the risk of metachronous CBC, but was associated with inferior BCSS.
我们评估了多灶性/多中心性(M/M)乳腺癌患者与单灶性(U)乳腺癌患者相比,在生存率和对侧乳腺癌(CBC)发生方面是否有不同的预后。方法:将诊断为I - III期乳腺癌的女性分为U型或M/M型疾病。前瞻性收集预后因素,并从乳腺癌预后单位数据库中获取。对CBC的发生率进行单因素和多因素分析,并绘制Kaplan - Meier曲线。结果:25320名女性符合纳入标准。U组与M/M组CBC的5年累积发生率分别为2.3%(95%可信区间2.1,2.5)和2.4%(95%可信区间1.6,3.4)(P = 0.349)。乳腺癌特异性生存率(BCSS)显示M/M型疾病的预后略差,RR = 1.174(95%可信区间1.004,1.372)。结论:M/M型乳腺癌并未增加异时性CBC的风险,但与较差的BCSS相关。